title: Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia.
abstract: Total body leukemic mass in patients with chronic lymphocytic leukemia (CLL) was measured by quantitation of total body potassium (TBK) with a whole-body counter. In addition, the predicted normal total body potassium (Kp) for each patient was calculated from an empirically derived relationship involving height, weight, age, and sex. Both the absolute TBK and the relative excess of total body potassium (TBK/Kp) were related to the stage of disease. Patients in the early stages of CLL were found to have lower TBK and TBK Kp than patients in the late stages of disease. Both of these parameters increased with the successively advanced stages of the disease. The clinically monitored reduction of leukemic cell mass following therapy was accompanied by reductions in TBK and TBK/Kp. Data presented support the notion that TBK/Kp is a useful indicator of the total body leukemic mass. Furthermore, the results of these studies quantitatively validate the proposed clinical staging system for CLL. Quantitation of TBK by a whole-body counter is an accurate and noninvasive procedure and does not require administration of isotopes.
mesh_terms: D006801:Humans; D007945:Leukemia, Lymphoid / Q000473:pathology / Q000503:physiopathology*; D007958:Leukocyte Count; D008214:Lymphocytes; D011188:Potassium; D014915:Whole-Body Counting
chemical_list: D011188:Potassium